Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis

F. Vescini, R. Attanasio, A. Balestrieri, F. Bandeira, S. Bonadonna, V. Camozzi, S. Cassibba, R. Cesareo, I. Chiodini, C. Maria Francucci, L. Gianotti, F. Grimaldi, R. Guglielmi, B. Madeo, C. Marcocci, A. Palermo, A. Scillitani, E. Vignali, V. Rochira, M. Zini

Research output: Contribution to journalArticle

Abstract

Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.

Original languageEnglish
Pages (from-to)807-834
Number of pages28
JournalJournal of Endocrinological Investigation
Volume39
Issue number7
DOIs
Publication statusPublished - Jul 1 2016

Fingerprint

Osteoporosis
Drug Therapy
Therapeutics
Aromatase Inhibitors
Postmenopausal Osteoporosis
Endocrinologists
methylamphotericin B
Pharmaceutical Preparations
Bone Density
Androgens
Prostatic Neoplasms
Breast Neoplasms
Safety

Keywords

  • Adherence
  • Androgen deprivation
  • Aromatase inhibitors
  • Bisphosphonates
  • Denosumab
  • Drug-induced osteoporosis
  • Fracture
  • Length of therapy
  • Male osteoporosis
  • Non-responder
  • Osteoporosis
  • SERMs
  • Side effects
  • Strontium ranelate
  • Teriparatide
  • Treatment

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Vescini, F., Attanasio, R., Balestrieri, A., Bandeira, F., Bonadonna, S., Camozzi, V., ... Zini, M. (2016). Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. Journal of Endocrinological Investigation, 39(7), 807-834. https://doi.org/10.1007/s40618-016-0434-8

Italian association of clinical endocrinologists (AME) position statement : drug therapy of osteoporosis. / Vescini, F.; Attanasio, R.; Balestrieri, A.; Bandeira, F.; Bonadonna, S.; Camozzi, V.; Cassibba, S.; Cesareo, R.; Chiodini, I.; Francucci, C. Maria; Gianotti, L.; Grimaldi, F.; Guglielmi, R.; Madeo, B.; Marcocci, C.; Palermo, A.; Scillitani, A.; Vignali, E.; Rochira, V.; Zini, M.

In: Journal of Endocrinological Investigation, Vol. 39, No. 7, 01.07.2016, p. 807-834.

Research output: Contribution to journalArticle

Vescini, F, Attanasio, R, Balestrieri, A, Bandeira, F, Bonadonna, S, Camozzi, V, Cassibba, S, Cesareo, R, Chiodini, I, Francucci, CM, Gianotti, L, Grimaldi, F, Guglielmi, R, Madeo, B, Marcocci, C, Palermo, A, Scillitani, A, Vignali, E, Rochira, V & Zini, M 2016, 'Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis', Journal of Endocrinological Investigation, vol. 39, no. 7, pp. 807-834. https://doi.org/10.1007/s40618-016-0434-8
Vescini, F. ; Attanasio, R. ; Balestrieri, A. ; Bandeira, F. ; Bonadonna, S. ; Camozzi, V. ; Cassibba, S. ; Cesareo, R. ; Chiodini, I. ; Francucci, C. Maria ; Gianotti, L. ; Grimaldi, F. ; Guglielmi, R. ; Madeo, B. ; Marcocci, C. ; Palermo, A. ; Scillitani, A. ; Vignali, E. ; Rochira, V. ; Zini, M. / Italian association of clinical endocrinologists (AME) position statement : drug therapy of osteoporosis. In: Journal of Endocrinological Investigation. 2016 ; Vol. 39, No. 7. pp. 807-834.
@article{331cae73931f4f61a006f2b1d816c690,
title = "Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis",
abstract = "Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.",
keywords = "Adherence, Androgen deprivation, Aromatase inhibitors, Bisphosphonates, Denosumab, Drug-induced osteoporosis, Fracture, Length of therapy, Male osteoporosis, Non-responder, Osteoporosis, SERMs, Side effects, Strontium ranelate, Teriparatide, Treatment",
author = "F. Vescini and R. Attanasio and A. Balestrieri and F. Bandeira and S. Bonadonna and V. Camozzi and S. Cassibba and R. Cesareo and I. Chiodini and Francucci, {C. Maria} and L. Gianotti and F. Grimaldi and R. Guglielmi and B. Madeo and C. Marcocci and A. Palermo and A. Scillitani and E. Vignali and V. Rochira and M. Zini",
year = "2016",
month = "7",
day = "1",
doi = "10.1007/s40618-016-0434-8",
language = "English",
volume = "39",
pages = "807--834",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "7",

}

TY - JOUR

T1 - Italian association of clinical endocrinologists (AME) position statement

T2 - drug therapy of osteoporosis

AU - Vescini, F.

AU - Attanasio, R.

AU - Balestrieri, A.

AU - Bandeira, F.

AU - Bonadonna, S.

AU - Camozzi, V.

AU - Cassibba, S.

AU - Cesareo, R.

AU - Chiodini, I.

AU - Francucci, C. Maria

AU - Gianotti, L.

AU - Grimaldi, F.

AU - Guglielmi, R.

AU - Madeo, B.

AU - Marcocci, C.

AU - Palermo, A.

AU - Scillitani, A.

AU - Vignali, E.

AU - Rochira, V.

AU - Zini, M.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.

AB - Treatment of osteoporosis is aimed to prevent fragility fractures and to stabilize or increase bone mineral density. Several drugs with different efficacy and safety profiles are available. The long-term therapeutic strategy should be planned, and the initial treatment should be selected according to the individual site-specific fracture risk and the need to give the maximal protection when the fracture risk is highest (i.e. in the late life). The present consensus focused on the strategies for the treatment of postmenopausal osteoporosis taking into consideration all the drugs available for this purpose. A short revision of the literature about treatment of secondary osteoporosis due both to androgen deprivation therapy for prostate cancer and to aromatase inhibitors for breast cancer was also performed. Also premenopausal females and males with osteoporosis are frequently seen in endocrine settings. Finally particular attention was paid to the tailoring of treatment as well as to its duration.

KW - Adherence

KW - Androgen deprivation

KW - Aromatase inhibitors

KW - Bisphosphonates

KW - Denosumab

KW - Drug-induced osteoporosis

KW - Fracture

KW - Length of therapy

KW - Male osteoporosis

KW - Non-responder

KW - Osteoporosis

KW - SERMs

KW - Side effects

KW - Strontium ranelate

KW - Teriparatide

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84975869384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975869384&partnerID=8YFLogxK

U2 - 10.1007/s40618-016-0434-8

DO - 10.1007/s40618-016-0434-8

M3 - Article

AN - SCOPUS:84975869384

VL - 39

SP - 807

EP - 834

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 7

ER -